{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-115766","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.288626+00:00","generated_at":"2026-06-08T08:41:14.479520+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cryoport Q3 revenue down 7% YoY, net loss widens to $0.31/share; affirms FY guidance","bullets":["Q3 revenue $56.2M (-7% YoY); net loss $15.3M ($0.31 loss per share) vs $7.3M ($0.15 loss) in Q3 2022.","Adjusted EBITDA negative $3.1M (vs positive $4.7M a year ago); operating costs rose to $41.2M.","Commercial cell/gene therapy revenue up 54% to $6.6M; supports record 670 clinical trials (81 Phase 3).","Affirms FY2023 revenue guidance $233-243M; cash & investments $465.9M at quarter end.","Repurchased $31.3M of convertible notes for $25.1M, recording $5.7M gain on debt extinguishment."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-115766","json":"https://secwatch.observer/filing/0001104659-23-115766.json","markdown":"https://secwatch.observer/filing/0001104659-23-115766.md","text":"https://secwatch.observer/filing/0001104659-23-115766.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465923115766/0001104659-23-115766-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465923115766/tm2330255d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:41:14.479520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1dfbdfb1cdfd25de047226cc04c43f799b9b16a2","claim":"Cryoport, Inc. reported the third quarter ended September 30, 2023 results: revenue $56.2 million. Guidance reaffirmed.","evidence_excerpt":"new therapy approvals and an additional seven label/ geographic expansions or moves to earlier lines of treatment approved. Financial Highlights Total revenue for Q3 2023 was $56.2 million compared to $60.5 million for Q3 2022, a year-over-year decrease of 7% or $4.3 million. • Biopharma/Pharma revenue was $47.0 million, down 3% or $1.6 million for Q3 2023 compared","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124524/000110465923115766/0001104659-23-115766-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$56.2 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}